20 articles
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
Tissue stiffness triggers a chain reaction — recruiting macrophages that generate DNA-damaging lipid byproducts — linking fibrosis directly to cancer initiation.
Large study reveals cancer survivors have higher biological age than cancer-free individuals, with strongest mortality predictions from epigenetic clocks.
Scientists discover how brain immune cells help cancer metastases grow and identify a potential drug to block this process.
Fibrotic tissue stiffness activates a cascade that recruits immune cells and generates DNA-damaging aldehydes, linking dense breast tissue to cancer risk.
Scientists discover how small cell lung cancer uses inflammation to become more aggressive and resistant to treatment.
Researchers discover CXCR6+ T cells drive deadly myocarditis from immune checkpoint inhibitors and find potential treatment target.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
A comprehensive review reveals how the senescence secretome suppresses tumors early but drives progression, resistance, and metastasis chronically.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Simple blood tests detecting microRNAs show promise for early prostate cancer detection, replacing painful biopsies with precision monitoring.
Specific mutational signatures accumulate linearly with age in normal tissues, offering a new window into why cancer risk rises exponentially as we get older.
New fusion model combines hypoxia and immune markers to predict hepatocellular carcinoma treatment success non-invasively.
New study identifies 7-gene signature linking air pollutants to hepatocellular carcinoma prognosis via immune dysfunction.
New framework reveals why immune cells fail to control tumors in metabolically active tissues, opening paths for better treatments.
Study identifies blood markers that distinguish long-term survivors from short-term survivors in brain cancer treatment.
Scientists identify protein and metabolic markers in blood that can catch lung cancer in early stages when treatment is most effective.
